Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...
Researchers found that, in patients with stage III NSCLC, treatment with cCRT and an ICI was safe, but treatment with cCRT and 2 ICIs led to “excessive mortality.” ...
THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
Diagnosed with stage 3B lung cancer in 2018, I joined a support group where I met Jim and Melanie, and learned about Jim's ...
A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...
Using preoperative chest CT scans, researchers identified novel preoperative biomarkers for lung cancer recurrence ...
Combination treatment with ibrilatazar and chemotherapy has demonstrated “promising efficacy and safety” in patients with advanced squamous non-small cell lung cancer (NSCLC), according to researchers ...
With 44,000 new diagnoses each year, non-small cell lung cancer is the second most frequent neoplasm in Italy after breast ...
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...
8d
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...
A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback